Tumor necrosis factor inhibitor therapy for rheumatoid arthritis

Stanley M Naguwa

doi:10.1196/annals.1361.115

Tumor necrosis factor inhibitor therapy for rheumatoid arthritis

Stanley M Naguwa

Rheumatology, Allergy, and Clinical Immunology

Research output: Contribution to journal › Article

8 Scopus citations

Abstract

The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.

Original language	English (US)
Pages (from-to)	709-715
Number of pages	7
Journal	Annals of the New York Academy of Sciences
Volume	1051
DOIs	https://doi.org/10.1196/annals.1361.115
State	Published - 2005

Keywords

Biologic response modifiers
Corticosteroids
Disease-modifying antirheumatic drugs
DMARDs
Rheumatoid arthritis
TNF-α inhibitors

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1196/annals.1361.115

Fingerprint Dive into the research topics of 'Tumor necrosis factor inhibitor therapy for rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this

Naguwa, S. M. (2005). Tumor necrosis factor inhibitor therapy for rheumatoid arthritis. Annals of the New York Academy of Sciences, 1051, 709-715. https://doi.org/10.1196/annals.1361.115

@article{817d2125829c4d06b0daae859252cc28,

title = "Tumor necrosis factor inhibitor therapy for rheumatoid arthritis",

abstract = "The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.",

keywords = "Biologic response modifiers, Corticosteroids, Disease-modifying antirheumatic drugs, DMARDs, Rheumatoid arthritis, TNF-α inhibitors",

author = "Naguwa, {Stanley M}",

year = "2005",

doi = "10.1196/annals.1361.115",

language = "English (US)",

volume = "1051",

pages = "709--715",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Tumor necrosis factor inhibitor therapy for rheumatoid arthritis

AU - Naguwa, Stanley M

PY - 2005

Y1 - 2005

N2 - The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.

AB - The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.

KW - Biologic response modifiers

KW - Corticosteroids

KW - Disease-modifying antirheumatic drugs

KW - DMARDs

KW - Rheumatoid arthritis

KW - TNF-α inhibitors

UR - http://www.scopus.com/inward/record.url?scp=25444482353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444482353&partnerID=8YFLogxK

U2 - 10.1196/annals.1361.115

DO - 10.1196/annals.1361.115

M3 - Article

C2 - 16127011

AN - SCOPUS:25444482353

VL - 1051

SP - 709

EP - 715

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -